Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Cancer Res. 2021 Jul 28;81(19):4910–4925. doi: 10.1158/0008-5472.CAN-21-0463

Figure 1. Validation of NIHCOLE upregulation in HCC and clinical associations.

Figure 1.

A, B NIHCOLE levels from RNA-Seq data were evaluated in paired peritumor (PT) and tumor (T) samples (n = 50 pairs) (A) or in all HCC samples (PT n = 50, T n = 374) deposited to TCGA (B). C-E Validation by qRT-PCR in the BCL-CUN cohort in all patient samples including healthy (H) liver biopsies (H n = 10, PT n = 17 and T n = 19) (C), in the paired PT/T pairs (n = 15 pairs) (D) or by RNA-seq (n = 10 pairs) (E). F, G Clinical associations with data from the TCGA (F, G) and INSERM cohort (n = 198) (F). See text for details. Scale, from lowest (red) to <0.05 (black) or >0.05 (blue), indicates p-value. H Survival probability of HCC patients categorized according to median NIHCOLE expression (n is indicated at each time point). I GBA analysis of NIHCOLE related coding-gene expression. Scale, from positive >10 (red) to negative <−10 indicates z-score. The significance of the statistical analysis (two-tailed Wilcoxon matched-pairs signed rank test in A, C, D, two-tailed Mann-Whitney test in B, Kruskal–Wallis ANOVA-test in E, two-tailed Student’s t test in F, G, and the logrank test in H) is indicated in each graph and summarized as: not significant (ns); * <0.05; **<0.01; ***<0.001; ****<0.0001. See algo Figures S1 and S2.